Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:assesses |
gptkb:acalabrutinib
|
| gptkbp:comparator |
gptkb:obinutuzumab_plus_chlorambucil
|
| gptkbp:endPoint |
progression-free survival
|
| gptkbp:enrollment |
535 patients
|
| https://www.w3.org/2000/01/rdf-schema#label |
ELEVATE-TN
|
| gptkbp:NCT_number |
gptkb:NCT02475681
|
| gptkbp:period |
Phase 3
|
| gptkbp:population |
treatment-naive CLL patients
|
| gptkbp:sponsor |
gptkb:AstraZeneca
|
| gptkbp:startYear |
2016
|
| gptkbp:studies |
chronic lymphocytic leukemia
|
| gptkbp:bfsParent |
gptkb:Calquence
|
| gptkbp:bfsLayer |
6
|